RESEARCH NOTES · 30 OCTOBER 2026
A promising research direction
Research into NAD-related compounds is exploring measurable effects on human metabolism. In a 10-week randomised, placebo-controlled study, oral nicotinamide mononucleotide (NMN) improved muscle insulin sensitivity in postmenopausal women with prediabetes who were overweight or obese. This is a useful signal for further investigation in that specific group. It does not establish a general anti-ageing effect or a benefit for everyone. Read the clinical trial.
A higher biomarker is not the same as better health
A 2026 systematic review covering studies through October 2025 found that oral NMN and nicotinamide riboside (NR) commonly increased NAD-related biomarkers. They were generally tolerated over the short study periods. However, effects on meaningful metabolic, physical and other health outcomes varied, and many results were null or limited to particular measures. The review concluded that clinical effectiveness for anti-ageing and general wellness remained inconclusive. Read the evidence review.
Keep the formulations separate
NMN and NR are NAD precursors; they are not equivalent to administering NAD+ itself. The review found no eligible clinical-outcome trials of intravenous or intramuscular NAD+ for anti-ageing or wellness. Oral-precursor results therefore cannot substantiate promises for NAD+ pens, injections or drips. Short-term tolerability also does not establish long-term safety. The constructive next step is better clinical research, rather than promises of rejuvenation or guaranteed energy improvements.
Educational summary, not personal medical advice or an endorsement of a supplier or product. No dosing or ordering guidance is provided. This editorial has not been independently medically reviewed. Sources checked 30 October 2026.